DAMORA THERAPEUTICS

Damora Therapeutics is a biotechnology company developing next‑generation, disease‑modifying biologics for mutant calreticulin‑driven myeloproliferative neoplasms (MPNs) such as essential thrombocythemia and myelofibrosis, with the mission of redefining the standard of care in these chronic hematologic cancers.